DelveInsight’s, “End-Stage Renal Disease - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in End-Stage Renal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
End-Stage Renal Disease: Overview
End-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease — the gradual loss of kidney function — reaches an advanced state. In end-stage renal disease, the kidneys are no longer able to work as they should to meet the body's needs. End stage renal disease (ESRD) is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10 to 15 percent of their normal capacity. When chronic kidney disease develops into ESRD, dialysis or a kidney transplant is necessary to stay alive. ESRD is caused most commonly due to diabetes and hypertension (high blood pressure). The treatments for ESRD are dialysis or a kidney transplant. In some cases, lifestyle changes and medications may help.
"End-Stage Renal Disease- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the End-Stage Renal Disease pipeline landscape is provided which includes the disease overview and End-Stage Renal Disease treatment guidelines. The assessment part of the report embraces, in depth End-Stage Renal Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.
This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
End-Stage Renal Disease Emerging Drugs
AB002: Aronora, Inc.
Mechanism of Action: Protein C stimulants. The phase 2 of clinical trials are going on to study safety and efficacy of AB002 in end stage renal disease patients on chronic hemodialysis.
ISIS 416858: Ionis Pharmaceuticals
ISIS 416858 is a Factor XI inhibitor. A phase 2 clinical study evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ISIS 416858 for participants with ESRD (end stage renal disease) receiving chronic hemodialysis as assessed by FXI activity reduction.
Further product details are provided in the report……..
This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for End-Stage Renal Disease. The companies which have their End-Stage Renal Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Aronora Inc., and others.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
End-Stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
End-Stage Renal Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
End-Stage Renal Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Late Stage Products (Phase III)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AB002: Aronora Inc.
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
End-Stage Renal Disease Key Companies
End-Stage Renal Disease Key Products
End-Stage Renal Disease- Unmet Needs
End-Stage Renal Disease- Market Drivers and Barriers
End-Stage Renal Disease- Future Perspectives and Conclusion
End-Stage Renal Disease Analyst Views
End-Stage Renal Disease Key Companies
Appendix
List of Table
Table 1: Total Products for End-Stage Renal Disease
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for End-Stage Renal Disease
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Aronora Inc.
• Ionis Pharmaceuticals
• Janssen Research & Development, LLC
• Ardelyx
